ReviewMolecular diagnosis & therapy2020
Liquid Biopsy Applications in the Clinic.
Review in Molecular diagnosis & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 53 citations in OpenAlex.
- Clinical Use of Liquid Biopsy in Metastatic Breast Cancer-An ESSO-EYSAC International Survey.Journal of surgical oncology · 2025Article
- Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis.Journal of translational medicine · 2024Review
- Microsatellite Instability in Urine: Breakthrough Method for Bladder Cancer Identification.Biomedicines · 2024Review
- Personalized treatment approach for HER2-positive metastatic breast cancer.Medical oncology (Northwood, London, England) · 2024Review
- MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing.Bioinformatics (Oxford, England) · 2024Article
- A Roadmap for the Rational Use of Biomarkers in Oral Disease Screening.Biomolecules · 2024Review
- Review
- Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.International journal of molecular sciences · 2023Review
- Optimal Parameter Configuration of a Microfluidic Chip for High-Throughput, Label-Free Circulating Tumor Cell Separation and Enrichment Based on Inertial Focusing.Diagnostics (Basel, Switzerland) · 2023Article
- Liquid Biopsies: Emerging role and clinical applications in solid tumours.Translational oncology · 2023Article
- Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.World journal of gastroenterology · 2023Review
- Liquid Biopsy in Adverse Neurodevelopment of Children: Problems and Prospects.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Exosomal circRNAs as promising liquid biopsy biomarkers for glioma.Frontiers in immunology · 2023Review
- Role of Liquid Biopsies in Rheumatoid Arthritis.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Article
- The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.International journal of molecular sciences · 2022Review
- RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma.World journal of gastrointestinal oncology · 2022Article
- Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.Non-coding RNA · 2022Review
- Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.Current issues in molecular biology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global liquid biopsy industry is expected to exceed $US5 billion by 2023. One application of liquid biopsy technology is the diagnosis of disease using biomarkers found in blood, urine, stool, saliva, and other biological samples from patients. These biomarkers could be DNA, RNA, protein, or even a cell. More recently, the use of cell-free DNA from plasma is emerging as an important minimally invasive tool for clinical diagnosis. The development of technology has increased the diversity of its application. Here, we discuss how liquid biopsies have been used in the clinic, and how personalized medicine are likely to use liquid biopsies in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.